All In Biotech

Drug Trial Radar · NCT02158572

Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System

A Single-arm, Open-label, Multicenter Phase 3 Study of the Contraceptive Efficacy, Safety and Tolerability of the AG200-15 Transdermal Contraceptive Delivery System (TCDS)

Last checked: Nov 19, 2026Latest source record: May 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,032

Actual

Start

Aug 2014

Primary completion

Nov 2016

Study completion Nov 2016

Sponsor

Lead sponsor
Agile TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Female only
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study of the efficacy of a contraceptive patch in 2100 healthy women for up to one year.

Conditions

  • Healthy

Interventions

  • AG200-15Drug

    Transdermal contraceptive delivery system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age Regardless of BMI, Intent-to-treat (ITT) Dataset.Time frame: 1 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.